+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome



Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome



Pediatric Dermatology 30(3): E30-E31



Dyshidrotic eczema is one of the rare cutaneous adverse effects of intravenous immunoglobulin therapy, usually seen in adults. We herein report the first pediatric case of severe dyshidrotic eczema occurring after intravenous immunoglobulin therapy for Kawasaki syndrome.

(PDF emailed within 0-6 h: $19.90)

Accession: 036332731

Download citation: RISBibTeXText

PMID: 22304420

DOI: 10.1111/j.1525-1470.2011.01717.x


Related references

Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease. Bmj Case Reports 12(3), 2019

Dyshidrotic eczema following intravenous immunoglobulin treatment. Cmaj 185(11): E530, 2013

Treatment of dyshidrotic eczema. What therapy is particularly successfull in dyshidrotic eczema of the hands?. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 22(8): 370, 1971

The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology 198(3): 265-269, 1999

Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. Journal of Drugs in Dermatology 2(3): 337-341, 2003

Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome. Archives of Dermatology 142(2): 247-248, 2006

Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease. International Archives of Allergy and Immunology 164(2): 83-88, 2014

Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease. Journal of Pediatric Hematology/Oncology 39(2): E100-E102, 2016

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?. Korean Circulation Journal 47(2): 179-181, 2017

A Case of Complete Resolution of Severe Plantar Dyshidrotic Eczema With Dupilumab. Journal of Drugs in Dermatology 18(2): 211-212, 2019

Intravenous immunoglobulin in Kawasaki syndrome: a progress report. Pediatric Infectious Disease 5(3 Suppl): S211-S215, 1986

Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. American Journal of Hematology 63(3): 160-161, 2000

Prednisolone added to intravenous immunoglobulin treatment improves outcome in children with severe Kawasaki disease. Archives of Disease in Childhood. Education and Practice Edition 98(2): 77-78, 2013

Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. Journal of Pediatrics 163(2): 521-526, 2013

Recommendations for intravenous immunoglobulin therapy of Kawasaki disease. Pediatric Infectious Disease Journal 11(11): 985-986, 1992